Decoding the cellular switchpoints of health and disease
Disease, exposures and treatment leave measurable marks in cellular biology.
Switchpoint Bio reads those marks.
Our platform brings together epigenomics and AI to turn that biology into decision-grade evidence for drug development and clinical research.
Solutions
Disease Biology & Biomarker Discovery
Reveal blood-based epigenomic signatures that define known and novel disease states and the cellular mechanisms driving them.
Patient Stratification & Trial Enrichment
Identify biologically defined patient groups to enrich trials and sharpen clinical readouts.
Treatment Response & Mechanism Readouts
Track cellular state changes during treatment to understand response, resistance, and mechanism of action.
“Switchpoint Bio is building a new way to read cellular biology from blood.
DNA methylation reveals which immune cells are present, their regulatory states, and how those states change with disease and treatment.
We founded Switchpoint Bio to make this biology visible at scale — because behind every data point is a patient waiting for the right treatment to find them.”
— Samuel Myllykangas, Co-Founder CEO
Biology leaves a record in blood. We read and decode it at scale.
Precision epigenomics at scale — one assay, many layers of biology. Circulating immune cells act as a systemic sensor, carrying a molecular record of the whole body in every blood draw — a record our platform reads, interprets, and turns into insight.